Obesity as a disease state: A new paradigm for diagnosis and treatment

Clinical Cornerstone

Volumn 9, Issue 4, 2009, Pages 9-29

  Aronne, Louis J ^a   Nelinson, Donald S ^b   Lillo, Joseph L ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b The Diabetes Consortium Inc Mountain Lakes   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIOBESITY AGENT; CONTRAVE; CYPROHEPTADINE; EMPATIC; EXENDIN 4; FATTY ACID; INCRETIN; INTERLEUKIN 6; LEPTIN; LORCASERIN; NALTREXONE; NEUROLEPTIC AGENT; PHENTERMINE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAMLINTIDE; PROTEINASE INHIBITOR; QNEXA; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONISAMIDE;

ADIPOSE TISSUE; ARTICLE; ATHEROSCLEROSIS; BEHAVIOR MODIFICATION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETOGENESIS; DIET THERAPY; DRUG USE; ECONOMIC ASPECT; ENDOTHELIUM LESION; FOOD INTAKE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPODYSTROPHY; MORBID OBESITY; OBESITY; PHYSICAL ACTIVITY; POLITICS; PREVALENCE; SIDE EFFECT; SOCIAL NETWORK; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ADIPOKINES; APPETITE DEPRESSANTS; BARIATRIC SURGERY; BODY SIZE; CARDIOVASCULAR DISEASES; CULTURAL CHARACTERISTICS; DIET; EXERCISE; FATTY ACIDS, NONESTERIFIED; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; METABOLIC DISEASES; OBESITY; RISK FACTORS; SOCIAL ENVIRONMENT; SOCIOECONOMIC FACTORS;

EID: 70349306533     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(09)80002-1     Document Type: Article

References (86)

1. World Health Organization. Obesity and overweight. Fact Sheet No. 311 (September 2006). http://www.who.int/mediacentre/factsheets/fs311/en/index.html Accessed January 13, 2009
2. Bray G.A. Medical consequences of obesity. J Clin Endocrinol Metab. 89 (2004) 2583-2589
3. Grundy S.M., Cleeman J.I., Daniels S.R., et al., the American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published corrections appear in Circulation. 2005;112:e297, e298]. Circulation. 112 (2005) 2735-2752
4. Consensus Report, AOA, ACOI, ACOFP, AAPA, The Diabetes Consortium. Addressing overweight and obesity: Evolving to a medical consensus. JAOA 108 Suppl 1 (2008) S2-S15
5. American Obesity Association. Treatment. Obesity is a chronic disease. http://obesity1.tempdomainname.com/subs/aoaresearch/ Accessed January 12, 2009
6. Bray G.A. The epidemic of obesity and changes in food intake: The Fluoride Hypothesis. Physiol Behav. 82 (2004) 115-121
7. Centers for Disease Control and Prevention. Prevalence of regular physical activity among adults-United States, 2001 and 2005. MMWR. 56 (2007) 1209-1212
8. Kimm S.Y., Glynn N.W., Kriska A.M., et al. Decline in physical activity in black girls and white girls during adolescence. N Engl J Med. 347 (2002) 709-715
9. Christakis N.A., and Fowler J.H. The spread of obesity in a large social network over 32 years. N Engl J Med. 357 (2007) 370-379
10. Kushner R.F., and Roth J.L. Assessment of the obese patient. Endocrinol Metab Clin North Am. 32 (2003) 915-933
11. Candib L.M. Obesity and diabetes in vulnerable populations: Reflection on proximal and distal causes [published correction appears in Ann Fam Med. 2008;6:85]. Ann Fam Med. 5 (2007) 547-556
12. Levitt N.S., and Lambert E.V. The foetal origins of the metabolic syndrome-a South African perspective. Cardiovasc J S Afr. 13 (2002) 179-180
13. Ozanne S.E., Fernandez-Twinn D., and Hales C.N. Fetal growth and adult diseases. Semin Perinatol 28 (2004) 81-87
14. Yajnik C.S. Early life origins of insulin resistance and type 2 diabetes in India and other Asian countries. J Nutr. 134 (2004) 205-210
15. Bindon J.R., and Baker P.T. Bergmann's rule and the thrifty genotype. Am J Phys Anthropol. 104 (1997) 201-210
16. Lev-Ran A. Human obesity: An evolutionary approach to understanding our bulging waistline. Diabetes Metab Res Rev. 17 (2001) 347-362
17. Caballero B. A nutrition paradox-underweight and obesity in developing countries. N Engl J Med. 352 (2005) 1514-1516
18. Popkin B.M. The nutrition transition and its health implications in lower-income countries. Public Health Nutr. 1 (1998) 5-21
19. Drewnowski A., and Popkin B.M. The nutrition transition: New trends in the global diet. Nutr Rev. 55 (1997) 31-43
20. Qvortrup M. Globalisation and obesity. Obes Pract. 1 (2005) 10-12
21. Barnett A.H. The importance of treating cardiometabolic risk factors in patients with type 2 diabetes. Diab Vasc Dis Res. 5 (2008) 9-14
22. Després J.P., Lemieux I., and Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ. 322 (2001) 716-720
23. Klein S., Allison D.B., Heymsfield S.B., et al., the Association for Weight Management and Obesity Prevention NAASOthe Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Waist circumference and cardiometabolic risk: A consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care. 30 (2007) 1647-1652
24. Colditz G.A., Willett W.C., Rotnitzky A., and Manson J.E. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 122 (1995) 481-486
25. Chan J.M., Rimm E.B., Colditz G.A., et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 17 (1994) 961-969
26. Carey V.J., Walters E.E., Colditz G.A., et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol. 145 (1997) 614-619
27. Rexrode K.M., Carey V.J., Hennekens C.H., et al. Abdominal adiposity and coronary heart disease in women. JAMA. 280 (1998) 1843-1848
28. Dagenais G.R., Yi Q., Mann J.F., et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J. 149 (2005) 54-60
29. Mokdad A.H., Marks J.S., Stroup D.F., and Gerberding J.L. Actual causes of death in the United States, 2000 [published corrections appear in JAMA. 2005;293:293-294, 298]. JAMA 291 (2004) 1238-1245
30. Fontaine K.R., Redden D.T., Wang C., et al. Years of life lost due to obesity. JAMA. 289 (2003) 187-193
31. Peeters A., Barendregt J.J., Willekens F., et al., NEDCOM, the Netherlands Epidemiology and Demography Compression of Morbidity Research Group. Obesity in adulthood and its consequences for life expectancy: A life-table analysis. Ann Intern Med. 138 (2003) 24-32
32. Allison D.B., Fontaine K.R., Manson J.E., et al. Annual deaths attributable to obesity in the United States. JAMA. 282 (1999) 1530-1538
33. Calle E.E., Thun M.J., Petrelli J.M., et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 341 (1999) 1097-1105
34. Wei M., Kampert J.B., Barlow C.E., et al. Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight, and obese men. JAMA. 282 (1999) 1547-1553
35. Stevens J., Cai J., Pamuk E.R., et al. The effect of age on the association between body-mass index and mortality. N Engl J Med. 338 (1998) 1-7
36. Jousilahti P., Tuomilehto J., Vartiainen E., et al. Body weight, cardiovascular risk factors, and coronary mortality. 15-Year follow-up of middle-aged men and women in eastern Finland. Circulation. 93 (1996) 1372-1379
37. Manson J.E., Willett W.C., Stampfer M.J., et al. Body weight and mortality among women. N Engl J Med. 333 (1995) 677-685
38. Adams K.F., Schatzkin A., Harris T.B., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 355 (2006) 763-778
39. Weisberg S.P., McCann D., Desai M., et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 112 (2003) 1796-1808
40. Lyon C.J., Law R.E., and Hsueh W.A. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology. 144 (2003) 2195-2200
41. Calabrò P., Limongelli G., Pacileo G., et al. The role of adiposity as a determinant of an inflammatory milieu. J Cardiovasc Med (Hagerstown) 9 (2008) 450-460
42. Nguyen M.T., Satoh H., Favelyukis S., et al. JNK and tumor necrosis factor-α mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem. 280 (2005) 35361-35371
43. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
44. Bastard J.P., Maachi M., Lagathu C., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17 (2006) 4-12
45. De Alvaro C., Teruel T., Hernandez R., and Lorenzo M. Tumor necrosis factor α produces insulin resistance in skeletal muscle by activation of inhibitor κB kinase in a p38 MAPK-dependent manner. J Biol Chem 279 (2004) 17070-17078
46. Greenberg A.S., and Obin M.S. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 83 Suppl (2006) 461S-465S
47. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 100 (1999) 2473-2476
48. Lau D.C., Dhillon B., Yan H., et al. Adipokines: Molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288 (2005) H2031-H2041
49. Rotter V., Nagaev I., and Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278 (2003) 45777-45784
50. Qureshi K., and Abrams G.A. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 13 (2007) 3540-3553
51. Glund S., Deshmukh A., Long Y.C., et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 56 (2007) 1630-1637
52. Tham D.M., Martin-McNulty B., Wang Y.X., et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 11 (2002) 21-30
53. Engeli S., Schling P., Gorzelniak K., et al. The adipose-tissue renin-angiotensin-aldosterone system: Role in the metabolic syndrome?. Int J Biochem Cell Biol. 35 (2003) 807-825
54. Goossens G.H., Jocken J.W., Blaak E.E., et al. Endocrine role of the renin-angiotensin system in human adipose tissue and muscle: Effect of beta-adrenergic stimulation. Hypertension 49 (2007) 542-547
55. Kohler H.P., and Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342 (2000) 1792-1801
56. Mutch N.J., Wilson H.M., and Booth N.A. Plasminogen activator inhibitor-1 and haemostasis in obesity. Proc Nutr Soc 60 (2001) 341-347
57. Trayhurn P., and Wood I.S. Adipokines: Inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92 (2004) 347-355
58. Després J.P. Abdominal obesity: The most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J Suppl 8 Suppl B (2006) B4-B12
59. Juhan-Vague I., Alessi M.C., and Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 28 (1996) 371-380
60. Leshan R.L., Björnholm M., Münzberg H., and Myers Jr. M.G. Leptin receptor signaling and action in the central nervous system. Obesity (Silver Spring) 14 Suppl 5 (2006) 208S-212S
61. Tilg H., and Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 14 (2008) 222-231
62. Ahima R.S. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 14 Suppl 5 (2006) 242S-249S
63. Cooke J.P., and Oka R.K. Does leptin cause vascular disease?. Circulation 106 (2002) 1904-1905
64. Berg A.H., Combs T.P., and Scherer P.E. ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13 (2002) 84-89
65. Yamauchi T., Kamon J., Minokoshi Y., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
66. Bruun J.M., Lihn A.S., Verdich C., et al. Regulation of adi-ponectin by adipose tissue-derived cytokines: In vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285 (2003) E527-E533
67. Maeda N., Takahashi M., Funahashi T., et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
68. Okamoto Y., Kihara S., Ouchi N., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106 (2002) 2767-2770
69. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103 (2001) 1057-1063
70. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
71. National Institutes of Health, the National Heart, Lung, and Blood Institute, and the North American Association for the Study of Obesity. Practical Guide to the Identification, Evaluation and Treatment of Overweight and Obesity in Adults (October 2000), National Institutes of Health, Bethesda, MD NIH publication 00-4084
72. Buse J.B., Ginsberg H.N., Bakris G.L., and the American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30 (2007) 162-172
73. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
74. Williamson D.A., and Perrin L.A. Behavioral therapy for obesity. Endocrinol Metab Clin North Am 25 (1996) 943-954
75. Wadden T.A., and Foster G.D. Behavioral treatment of obesity. Med Clin North Am. 84 (2000) 441-461 vii
76. Hainer V., Toplak H., and Mitrakou A. Treatment modalities of obesity: What fits whom?. Diabetes Care 31 Suppl 2 (2008) S269-S277
77. Dansinger M.L., Gleason J.A., Griffith J.L., et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: A randomized trial. JAMA 293 (2005) 43-53
78. Mann T., Tomiyama J., Westling E., et al. Medicare's search for effective obesity treatments: Diets are not the answer. Am Psychol 62 (2007) 220-233
79. Wadden T.A., Berkowitz R.I., Womble L.G., et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 353 (2005) 2111-2120
80. Rucker D., Padwal R., Li S.K., et al. Long term pharma-cotherapy for obesity and overweight: Updated meta-analysis [published correction appears online at http://bmj.com/cgi/content/full/335/7629/0-a]. BMJ 335 (2007) 1194-1199
81. Nissen S.E., Nicholls S.J., Wolski K., et al., the STRADI-VARIUS Investigators. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: The STRADIVARIUS randomized controlled trial. JAMA 299 (2008) 1547-1560
82. Huizinga M.M. Weight-loss pharmacotherapy: A brief review. Clin Diabetes 25 (2007) 135-140
83. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: A systematic review and meta-analysis [published correction appears in JAMA. 2005;293:1728]. JAMA 292 (2004) 1724-1737
84. Adams T.D., Gress R.E., Smith S.C., et al. Long-term mortality after gastric bypass surgery. N Engl J Med 357 (2007) 753-761
85. Sjöström L., Lindroos A.K., Peltonen M., et al., the Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351 (2004) 2683-2693
86. Sjöström L., Narbro K., Sjöström C.D., et al., the Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357 (2007) 741-752